Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162375 | 0.84 | CA12 (0.41) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL29911112 | 0.83 | CA12 (0.48) | CA12CA1CA2CA9MAPT | |
| SCHEMBL285573 | 0.77 | RAB9A (0.66) | MAPTRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL15104532 | 0.76 | RAB9A (0.45) | CA12CA1CA2CA9MAPT | |
| SCHEMBL22939875 | 0.75 | RAB9A (0.44) | CA12CA1CA2CA9MAPT | |
| SCHEMBL29660330 | 0.74 | RAB9A (0.50) | MAPTRAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL595766 | 0.74 | MAOA (0.50) | MAPTRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL24045452 | 0.74 | CA12 (0.50) | CA12CA1CA2CA9MAPT | |
| SCHEMBL3398237 | 0.73 | RAB9A (0.42) | MAPTRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL961587 | 0.72 | CA12 (0.52) | L3MBTL1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289698-A1 | INHIBITORS OF HUMAN ATGL | Karl-Franzens-Universität Graz (AT) | 2022-09-15 | — | — | US | disclosed |
| EP-4003955-A1 | INHIBITORS OF HUMAN ATGL | Karl-Franzens-Universität Graz (AT) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289698-A1 | INHIBITORS OF HUMAN ATGL | LIPC, LIPG, PNLIP | L3MBTL1 268/4885CA12 4884/4885CA1 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.